Tropifexor is an investigational drug that acts as an agonist of the farnesoid X receptor (FXR). It was discovered by researchers at Novartis and the Novartis Research Foundation Institute for Genomics.
Rats orally treated with tropifexor (0.03 to 1 mg/kg) showed upregulation of the FXR target genes BSEP and SHP, while downregulation of CYP8B1. Its EC50 for FXR is between 0.2 and 0.26 nM, depending on the biochemical assay.
Synonym
LJN452; LJN-452; LJN452; CS-2712; CPD1549; Tropifexor; Tropifexor(LJN452); LJN452; LJN452, Tropifexor; 2-[(1R, 3r, 5S)-3-({5-cyclopropyl-3-Chemicalbook[2-(trifluoromethoxy)phenyl]-1, 2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1, 3-benzothiazole-6-carboxylicacid